# Elite Capital

> Elite Capital is a VC fund in Beijing backing Health Care, Biotechnology and Pharmaceutical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 5
- Last investment: Feb 2023
- Lead investor: 20%
- Last updated: Aug 2026
- Website: http://elite-capital.com

Elite Capital is a venture capital / private equity firm targeting life sciences companies; they have both a RMB and a USD fund.Elite Capital USD Fund targets innovative U.S. medical device and biopharma companies with strong U.S. and China market opportunities. In addition to capital, Elite Capital could provide accelerated, cost-effectivedevelopment of the China market. Support services include China management team recruitment, Chinese clinical trials, CFDA regulatory filing and approval guidance, strategic planning and business development.Elite Capital RMB Fund targets China domestic life sciences companies. They target both larger companies at the cusp of IPO, as well as smaller companies with strong product portfolio and great upside. In addition, the RMB fund will provide capital to incubate leading technologies and products from overseas in China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Biotechnology | 3 | 60% |
| Pharmaceutical | 2 | 40% |
| Energy | 1 | 20% |
| Medical | 1 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 60% |
| Series B | 2 | 40% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 4 | 80% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Linkcharging Technology | LINCHR specializes in the research and development of energy vehicle charging equipment, on-board charging, new energy microgrid, and intelligent detection, providing one-stop solutions for new energy vehicle applications. | $29.7M | Series A | Feb 01, 2023 |  |
| ExcelMab | ExcelMab develops a series of anti-tumor bispecific antibody drugs for cancer patients. | $1.4M | Series A | Mar 12, 2020 |  |
| Haihe Biopharma | HaiHe Biopharma is a developer of innovative anti tumor drugs designed to overcome complex diseases and improve pharmacological evaluation. The company focuses on discovery, development and commercialization of innovative anti-tumor drugs, pharmacological efficacy evaluation and provide products including novel topoisomerase I inhibitors and oralc-Met highly selective inhibitors, enabling customers to improve their health conditions and research quality in an efficient manner. | $146.6M | Series B | Feb 11, 2019 |  |
| Meichuang Technology | Mechuang Technology initially focused on database operation and maintenance and entered the data security market in 2007. At present, the company has four major product lines, including: data security, data management, disaster recovery backup, and intelligent operation & maintenance. These four major businesses form the company’s overallsolution for data security. | $14.2M | Series B | Sep 20, 2018 |  |
| KBP Biosciences | KBP is a world-class biotechnology research & development organization dedicated to providing innovative therapies for unmet medical needs. | $76M | Series A | Jan 05, 2018 |  |

5 of 5 investments shown.

## Co-investors
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 2 deals together
- [Advantech Capital](https://shizune.co/investors/profile/advantech-capital) — VC Fund, 1 deal together
- [Atlas Capital LLC](https://shizune.co/investors/profile/atlas-capital-llc) — VC Fund, 1 deal together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 1 deal together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together
- [CASH Capital](https://shizune.co/investors/profile/cash-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Elite Capital invest in?

Elite Capital invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Elite Capital last invest?

The most recent investment recorded for Elite Capital closed in Feb 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co